Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Beuvry – page 36

1 417 clinical trials in Beuvry, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Beuvry at a glance
1 417
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 417 trials in Beuvry

Open in trial search

Endometrial cancer+3

Recruiting

Study on the Safety and Effects of Farletuzumab Ecteribulin for Patients with Ovarian, Breast, Endometrial, and Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Eisai Limited

Endometrial cancer+3

Recruiting

Study of E7386 and Lenvatinib for Patients with Liver, Colon, Endometrial, or Other Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Eisai Limited

B-cell lymphoma recurrent+1

Recruiting

Study on MB-CART2019.1 for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible for High-Dose Chemotherapy and Stem Cell Transplantation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Oxaliplatin
  • Sponsor:Miltenyi Biomedicine GmbH

Glioblastoma

Recruiting

Study on Lomustine with or without Additional Brain Radiation for Patients with Recurrent Glioblastoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lomustine
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Colorectal cancer+5

Recruiting

Study on Long-Term Safety of Trastuzumab Deruxtecan for Patients with Advanced HER2-Positive or HER2-Mutated Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Anaplastic large cell lymphoma T- and null-cell types+3

Recruiting

Study of Crizotinib and Temsirolimus for Children with ALK, ROS1, or MET Positive Cancers, Including Neuroblastoma and Rhabdomyosarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Crizotinib
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Neoplasm

Recruiting

Study on the Safety and Efficacy of Tretinoin with Radiation Therapy for Patients with Oligometastatic Solid Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tretinoin
  • Sponsor:Institut Gustave Roussy

Major depression

Recruiting

Study on Lumateperone for Patients with Major Depressive Disorder Not Responding to Antidepressants

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lumateperone
  • Sponsor:Intra-Cellular Therapies Inc.

Still's disease

Recruiting

Study of apremilast compared to placebo in children aged 5-17 years with juvenile psoriatic arthritis

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Apremilast
  • Sponsor:Amgen Inc.

Vulval cancer

Recruiting

Study on the Safety of Using Chemoradiation with Cisplatin and Carboplatin for Early-Stage Vulvar Cancer Patients with Macrometastasis in Sentinel Lymph Node

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Universitair Medisch Centrum Groningen

Neuroendocrine tumour of the lung

Recruiting

Study on Durvalumab, Etoposide, and Platinum Drug Combination for First-Line Treatment of Advanced Large-Cell Neuroendocrine Lung Cancer Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Centre Leon Berard

Hormone-refractory prostate cancer

Recruiting

Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy and Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Beuvry

What the registry says about research in the country

01 Oncology Research - Digestive System

Several groundbreaking trials focusing on gastrointestinal cancers, including studies evaluating novel treatments for esophageal squamous cell carcinoma and advanced colorectal cancer. Research includes innovative combination therapies and targeted treatments for specific genetic mutations.

  • Esophageal Cancer Treatment
  • Colorectal Cancer Therapies
  • Pancreatic Adenocarcinoma Studies
02 Respiratory and Lung Cancer Research

Innovative studies examining treatments for non-small cell lung cancer, including immunotherapy combinations and radiation therapy approaches. Research focuses on improving outcomes for patients with advanced disease stages.

  • Advanced NSCLC Treatments
  • Immunotherapy Combinations
  • Radiation Therapy Protocols
03 Prostate and Breast Cancer Studies

Comprehensive research into hormone-dependent cancers, investigating new treatment approaches for castrate-resistant prostate cancer and ER+/HER2- breast cancer. Studies include both early-stage and advanced disease management.

  • Prostate Cancer Therapeutics
  • Breast Cancer Treatments
  • Hormone Therapy Research
04 Infectious Disease and Critical Care

Studies examining treatments for respiratory tract infections and severe infections in intensive care settings. Research includes antibiotic alternatives and management strategies for septic shock.

  • Respiratory Infections
  • Antibiotic Studies
  • Critical Care Interventions
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.